Enhancement of Fas-ligand-mediated programmed cell death by taurolidine

Anticancer Research

Volumn 23, Issue 3 B, 2003, Pages 2309-2314

  Stendel, Ruediger ^a   Scheurer, Louis ^b   Stoltenburg Didinger, Gisela ^b   Brock, Mario ^a   Möhler, Hanns ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Free Univ Berlin Hindenburgdamm 30 ^*

Author keywords

Apoptosis; Brain tumor; Glioblastoma; Programmed cell death

Indexed keywords

DNA; FAS LIGAND; TAUROLIDINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN CANCER; CALCULATION; CANCER CELL CULTURE; CELL DEATH; CELL DESTRUCTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ELECTRON MICROSCOPY; FLOW CYTOMETRY; GLIOMA CELL; HUMAN; HUMAN CELL; IC 50; MICROSCOPY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ASTROCYTOMA; CELL SURVIVAL; FAS LIGAND PROTEIN; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; MEMBRANE GLYCOPROTEINS; TAURINE; THIADIAZINES; TUMOR CELLS, CULTURED;

EID: 0041805725     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Knight BI, Skellern GG and Smail GA: NMR Studies and GC analysis of the antibacterial agent taurolidine. J Pharmacol Scienc 72: 705-707, 1983.
2. Bieselt R: Chirurgische Therapie des Pleuraempyems mit Taurolin. Langenbecks Arch Chir 382: S42-S46, 1997.
3. Jurewitsch B, Lee T, Park J and Jeejeebhoy K: Taurolidine 2% as an antimicrobial lock solution for prevention of recurrent catheter-related bloodstream infections. J Parenter Enteral Nutr 22: 242-244, 1998.
4. Stendel R, Stoltenburg-Didinger G and Brock M: The aminosulphonic acid derivative taurolidine induces apoptotic changes in brain tumor cells. [abstract] Presented at the 12th World Congress of Neurosurgery. Sydney, Australia, 2001.
5. Stendel R, Stoltenburg-Didinger G, Lotte Al-Keikh C, Wattrodt M and Brock M: The effect of taurolidine on brain tumor cells. Anticancer Res 22: 809-814, 2002.
6. Calabresi P, Goulette FA and Darnowski JW: Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 61: 6816-6821, 2001.
7. Ashkenazi H and Dixit M: Death receptors: signaling and modulation. Science 281: 1305-1308, 1998.
8. Thornberry NA and Lazebnik Y: Caspases: enemies within. Science 281: 1312-1316., 1998.
9. Frei K, Ambar B, Adachi N, Yonekawa Y and Fontana A: Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1 ligand-mediated apoptosis. J Neuroimmunol 87: 105-113, 1998.
10. Schlappbach R and Fontana A: Differential activity of bcl-2 and ICE enzyme family protease inhibitors on Fas and puromycine induced apoptosis in glioma cells. Acta Biochem Biophys 1359: 174-180, 1997.
11. Spector DL, Goldman RD and Leinwand LA: Culture and biochemical analysis of cells. In: Cells. A Laboratory Manual. (1st edition). New York: Cold Spring Harbor Laboratory Press, 1998, Vol 1, pp 15.13-15.14.
12. Browne MK: Pharmacological and clinical studies on Taurolin. In: A New Concept in Antimicrobial Chemotherapy for Surgical Infection. (Bruckner WL, Pfirrmann RW eds):, ed. Baltimore: Urban & Schwarzenberg, 1985, pp 51-63.
13. McCartney AC and Browne MK: Clinical studies on administration of taurolidine in severe sepsis: a preliminary study. In: Bacterial Endotoxins: Pathophysiological Effects, Clinical Significance and Pharmacological Control. (New York: Alan R.Liss Inc., 1988, p 130).
14. Moser G and Martin MD: Forty cases of peritonitis treated without antibiotics:the intraperitoneal and intravenous use of Taurolin. Praxis 67: 425-428, 1978.
15. Rosman C, Westerveld GJ, van Oeveren W, Kooi K and Bleichrodt RP: Effect of intraperitoneal antimicrobials on the concentration of bacteria, endotoxin, and tumor necrosis factor in abdominal fluid and plasma in rats. Eur Surg Res 28: 351-360, 1996.
16. Blenkharn IJ: The differential cytotoxicity of Taurolin. Data on file-Geistlich Pharma:, 1986.